Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dyslipidemia

Free Subscription Articles published in Curr Opin Lipidol Retrieve available abstracts of 61 articles: HTML format

Single Articles

June 2024
1. MULDER JWCM, Kusters DM, Roeters van Lennep JE, Hutten BA, et al
   Lipid metabolism during pregnancy: consequences for mother and child.
   Curr Opin Lipidol. 2024;35:133-140.
   PubMed     Abstract available
   
   
   April 2024
2. RASMUSSEN KL, Frikke-Schmidt R
   The current state of apolipoprotein E in dyslipidemia.
   Curr Opin Lipidol. 2024;35:78-84.
   PubMed     Abstract available
   
   
   
3. WEN Y, Chen YQ, Konrad RJ
   Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism.
   Curr Opin Lipidol. 2024;35:58-65.
   PubMed     Abstract available
   
   
   February 2024
4. CHAN DC, Watts GF
   ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
   Curr Opin Lipidol. 2024 Feb 20. doi: 10.1097/MOL.0000000000000920.
   PubMed     Abstract available
   
   
   
5. VAN DEN BOSCH SE, Hutten BA, Corpeleijn WE, Kusters DM, et al
   Familial hypercholesterolemia in children and the importance of early treatment.
   Curr Opin Lipidol. 2024 Feb 15. doi: 10.1097/MOL.0000000000000926.
   PubMed     Abstract available
   
   
   
6. PAPONJA K, Pecin I, Reiner Z, Banach M, et al
   Bempedoic acid: new evidence and recommendations on use.
   Curr Opin Lipidol. 2024;35:41-50.
   PubMed     Abstract available
   
   
   
7. ZHANG Y, de Ferranti SD, Moran AE
   Genetic testing for familial hypercholesterolemia.
   Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
   PubMed     Abstract available
   
   
   December 2023
8. PERERA SD, Hegele RA
   Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
   Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
   PubMed     Abstract available
   
   
   
9. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
   Predictors of cardiovascular risk in familial hypercholesterolemia.
   Curr Opin Lipidol. 2023;34:272-277.
   PubMed     Abstract available
   
   
   
10. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
    The pathophysiology of excess plasma-free cholesterol.
    Curr Opin Lipidol. 2023;34:278-286.
    PubMed     Abstract available
    
    
    
11. KARALIS DG
    Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:252-258.
    PubMed     Abstract available
    
    
    November 2023
12. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    PubMed     Abstract available
    
    
    October 2023
13. CHATTOPADHYAY A, Reddy ST, Fogelman AM
    The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis.
    Curr Opin Lipidol. 2023;34:196-200.
    PubMed     Abstract available
    
    
    August 2023
14. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    PubMed     Abstract available
    
    
    June 2023
15. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    PubMed     Abstract available
    
    
    
16. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    PubMed     Abstract available
    
    
    April 2023
17. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    PubMed     Abstract available
    
    
    
18. HEGELE RA
    DNA testing in dyslipidemia: attitudes and complexities.
    Curr Opin Lipidol. 2023;34:33-34.
    PubMed    
    
    
    March 2023
19. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    PubMed     Abstract available
    
    
    February 2023
20. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    PubMed     Abstract available
    
    
    January 2023
21. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    PubMed     Abstract available
    
    
    December 2022
22. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    PubMed     Abstract available
    
    
    
23. WEI T, Cho L
    Recent lipoprotein(a) trials.
    Curr Opin Lipidol. 2022;33:301-308.
    PubMed     Abstract available
    
    
    
24. MENDOZA MF, Lavie CJ
    Clinical associations between exercise and lipoproteins.
    Curr Opin Lipidol. 2022;33:364-373.
    PubMed     Abstract available
    
    
    
25. TRAMONTANO D, Bini S, D'Erasmo L, Arca M, et al
    Recent Apolipoprotein CIII trials.
    Curr Opin Lipidol. 2022;33:309-318.
    PubMed     Abstract available
    
    
    October 2022
26. TROMP TR, Cuchel M
    New algorithms for treating homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2022 Oct 5. pii: 00041433-990000000-00014.
    PubMed     Abstract available
    
    
    
27. SCIPIONE CA, Cybulsky MI
    Early atherogenesis: new insights from new approaches.
    Curr Opin Lipidol. 2022;33:271-276.
    PubMed     Abstract available
    
    
    August 2022
28. MARTINS J, Rossouw HM, Pillay TS
    How should low-density lipoprotein cholesterol be calculated in 2022?
    Curr Opin Lipidol. 2022;33:237-256.
    PubMed     Abstract available
    
    
    July 2022
29. LEREN TP, Bogsrud MP
    Cascade screening for familial hypercholesterolemia should be organized at a national level.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
    PubMed     Abstract available
    
    
    
30. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
    Lipoprotein (a) in familial hypercholesterolaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
    PubMed     Abstract available
    
    
    
31. PAQUETTE M, Bernard S, Baass A
    Diagnosis of remnant hyperlipidaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
    PubMed     Abstract available
    
    
    June 2022
32. THEROND P, Chapman MJ
    Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment.
    Curr Opin Lipidol. 2022;33:199-207.
    PubMed     Abstract available
    
    
    April 2022
33. WHITTAKER MN, Musunuru K
    Therapeutic application of genome editing in dyslipidemia.
    Curr Opin Lipidol. 2022;33:133-138.
    PubMed     Abstract available
    
    
    February 2022
34. SACKS FM, Andraski AB
    Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies.
    Curr Opin Lipidol. 2022;33:1-15.
    PubMed     Abstract available
    
    
    December 2021
35. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
    Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
    PubMed     Abstract available
    
    
    
36. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available
    
    
    
37. CHAN DC, Ying Q, Watts GF
    Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.
    Curr Opin Lipidol. 2021;32:378-385.
    PubMed     Abstract available
    
    
    
38. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    PubMed     Abstract available
    
    
    
39. KERSTEN S
    ANGPTL3 as therapeutic target.
    Curr Opin Lipidol. 2021;32:335-341.
    PubMed     Abstract available
    
    
    October 2021
40. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available
    
    
    
41. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available
    
    
    
42. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available
    
    
    September 2021
43. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available
    
    
    August 2021
44. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    PubMed     Abstract available
    
    
    
45. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    PubMed    
    
    
    June 2021
46. BERBERICH AJ, Hegele RA
    Lipid effects of glucagon-like peptide 1 receptor analogs.
    Curr Opin Lipidol. 2021;32:191-199.
    PubMed     Abstract available
    
    
    April 2021
47. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available
    
    
    
48. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    PubMed     Abstract available
    
    
    
49. WAND H, Knowles JW, Clarke SL
    The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
    Curr Opin Lipidol. 2021;32:89-95.
    PubMed     Abstract available
    
    
    
50. BROWN EE
    The genetic counselor's role in management of patients with dyslipidemia.
    Curr Opin Lipidol. 2021;32:83-88.
    PubMed     Abstract available
    
    
    
51. TRINDER M, Brunham LR
    Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance.
    Curr Opin Lipidol. 2021;32:103-111.
    PubMed     Abstract available
    
    
    
52. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    PubMed     Abstract available
    
    
    February 2021
53. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available
    
    
    October 2020
54. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available
    
    
    
55. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available
    
    
    September 2020
56. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available
    
    
    June 2020
57. SORAN H, Cooper JA, Durrington PN, Capps N, et al
    Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register.
    Curr Opin Lipidol. 2020 Jun 28. doi: 10.1097/MOL.0000000000000692.
    PubMed     Abstract available
    
    
    
58. BELANGER AM, Akioyamen L, Alothman L, Genest J, et al
    Evidence for improved survival with treatment of homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Jun 8. doi: 10.1097/MOL.0000000000000686.
    PubMed     Abstract available
    
    
    April 2020
59. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    PubMed     Abstract available
    
    
    
60. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    PubMed     Abstract available
    
    
    January 2020
61. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.